Abiomed (ABMD) and Cambrex (CBM) have been standout performers in IBD’s medical product industry group. Both stocks are extended now, but the good news is that several other names in the group are setting up for potential moves higher. Headed into Thursday, the Medical-Products group ranked 16th out of the 197 groups ranked by IBD, based on six-month price performance. A look at the group shows that innovation is alive and well.